Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models.

PURPOSE To determine the efficacy of combining radiation (XRT) with a dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor inhibitor, AEE788, in prostate cancer models with different levels of EGFR expression. METHODS AND MATERIALS Immunoblotting was performed for EGFR, phosphorylated-EGFR, and phosphorylated-AKT in prostate cancer cells. Clonogenic assays were performed on DU145, PC-3, and human umbilical vein endothelial cells treated with XRT +/- AEE788. Tumor xenografts were established for DU145 and PC-3 on hind limbs of athymic nude mice assigned to four treatment groups: (1) control, (2) AEE788, (3) XRT, and (4) AEE788 + XRT. Tumor blood flow and growth measurements were performed using immunohistochemistry and imaging. RESULTS AEE788 effectively decreased phosphorylated-EGFR and phosphorylated-AKT levels in DU145 and PC-3 cells. Clonogenic assays showed no radiosensitization for DU145 and PC-3 colonies treated with AEE788 + XRT. However, AEE788 caused decreased proliferation in DU145 cells. AEE788 showed a radiosensitization effect in human umbilical vein endothelial cells and increased apoptosis susceptibility. Concurrent AEE788 + XRT compared with either alone led to significant tumor growth delay in DU145 tumors. Conversely, PC-3 tumors derived no added benefit from combined-modality therapy. In DU145 tumors, a significant decrease in tumor blood flow with combination therapy was shown by using power Doppler sonography and tumor blood vessel destruction on immunohistochemistry. Maldi-spectrometry (MS) imaging showed that AEE788 is bioavailable and heterogeneously distributed in DU145 tumors undergoing therapy. CONCLUSIONS AEE788 + XRT showed efficacy in vitro/in vivo with DU145-based cell models, whereas PC-3-based models were adequately treated with XRT alone without added benefit from combination therapy. These findings correlated with differences in EGFR expression and showed effects on both tumor cell proliferation and vascular destruction.

[1]  D. Nam,et al.  Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. , 2005, Neoplasia.

[2]  Stefania Staibano,et al.  Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  A. Jemal,et al.  Geographic Patterns of Prostate Cancer Mortality and Variations in Access to Medical Care in the United States , 2005, Cancer Epidemiology Biomarkers & Prevention.

[4]  Walter A. Korfmacher,et al.  Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. , 2003, Journal of mass spectrometry : JMS.

[5]  D. Kuban,et al.  Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. , 2005, International journal of radiation oncology, biology, physics.

[6]  Michael Cross,et al.  Growth factors in development, transformation, and tumorigenesis , 1991, Cell.

[7]  C. Bucana,et al.  Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade , 2004, Cancer Research.

[8]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[9]  Gerald McMahon,et al.  SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. , 2003, Cancer research.

[10]  K. Ang,et al.  C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. , 2001, International journal of radiation oncology, biology, physics.

[11]  Kenji Yokoi,et al.  Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. , 2005, Cancer research.

[12]  H. Scher,et al.  Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Richard M Caprioli,et al.  Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Response to Molecular Therapeutics , 2004, Cancer Research.

[14]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Tilley,et al.  Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. , 1997, The Journal of urology.

[16]  D. Hallahan,et al.  Sonographic Depiction of Changes of Tumor Vascularity in Response to Various Therapies , 2005, Ultrasound quarterly.

[17]  C. Bucana,et al.  Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. , 2005, Cancer research.

[18]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[19]  Laetitia Padovani,et al.  Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation , 2005, Molecular Cancer Therapeutics.

[20]  Adrian L Harris,et al.  Mechanisms of Disease: angiogenesis in urologic malignancies , 2006, Nature Clinical Practice Urology.

[21]  J. Speight,et al.  Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[23]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[24]  D. Cosgrove,et al.  Angiogenesis imaging in the management of prostate cancer , 2005, Nature Clinical Practice Urology.

[25]  G. Auclerc,et al.  Management of advanced prostate cancer. , 2000, The oncologist.

[26]  S. Varambally,et al.  Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition , 2006, International journal of cancer.

[27]  K. Pienta,et al.  Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[29]  G. Stamp,et al.  Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. , 2004, Neoplasia.

[30]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[31]  J. Mestan,et al.  AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. , 2004, Cancer research.

[32]  M. Mandal,et al.  Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788 , 2005, Molecular Cancer Therapeutics.

[33]  A. Sood,et al.  Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors , 2005, Clinical Cancer Research.

[34]  K. Ang,et al.  Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. , 2004, International journal of radiation oncology, biology, physics.

[35]  P. Majumder,et al.  Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate. , 1998, Cancer letters.

[36]  C. Bucana,et al.  AEE788, a Dual Tyrosine Kinase Receptor Inhibitor, Induces Endothelial Cell Apoptosis in Human Cutaneous Squamous Cell Carcinoma Xenografts in Nude Mice , 2005, Clinical Cancer Research.

[37]  Chao-yuan Huang,et al.  Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. , 2006, Biochemical pharmacology.

[38]  A. Ullrich,et al.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.

[39]  M. Hussain,et al.  Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes , 2005, Cancer Chemotherapy and Pharmacology.